HK1258508A1 - 用免疫球蛋白單可變結構域治療ttp的方法及其用途 - Google Patents

用免疫球蛋白單可變結構域治療ttp的方法及其用途

Info

Publication number
HK1258508A1
HK1258508A1 HK19100857.1A HK19100857A HK1258508A1 HK 1258508 A1 HK1258508 A1 HK 1258508A1 HK 19100857 A HK19100857 A HK 19100857A HK 1258508 A1 HK1258508 A1 HK 1258508A1
Authority
HK
Hong Kong
Prior art keywords
methods
variable domains
single variable
immunoglobulin single
treating ttp
Prior art date
Application number
HK19100857.1A
Other languages
English (en)
Inventor
Christian Duby
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of HK1258508A1 publication Critical patent/HK1258508A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK19100857.1A 2014-06-16 2019-01-17 用免疫球蛋白單可變結構域治療ttp的方法及其用途 HK1258508A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2013007A NL2013007B1 (en) 2014-06-16 2014-06-16 Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
US201462030817P 2014-07-30 2014-07-30

Publications (1)

Publication Number Publication Date
HK1258508A1 true HK1258508A1 (zh) 2019-11-15

Family

ID=51541255

Family Applications (3)

Application Number Title Priority Date Filing Date
HK18115787.5A HK1256730A1 (zh) 2014-06-16 2018-12-10 在治療ttp的方法中使用的免疫球蛋白單可變結構域
HK18115789.3A HK1256731A1 (zh) 2014-06-16 2018-12-10 在治療ttp的方法中使用的免疫球蛋白單可變結構域
HK19100857.1A HK1258508A1 (zh) 2014-06-16 2019-01-17 用免疫球蛋白單可變結構域治療ttp的方法及其用途

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK18115787.5A HK1256730A1 (zh) 2014-06-16 2018-12-10 在治療ttp的方法中使用的免疫球蛋白單可變結構域
HK18115789.3A HK1256731A1 (zh) 2014-06-16 2018-12-10 在治療ttp的方法中使用的免疫球蛋白單可變結構域

Country Status (16)

Country Link
US (5) US10858445B2 (zh)
EP (6) EP3154569B1 (zh)
JP (3) JP6688746B2 (zh)
KR (2) KR102403388B1 (zh)
CN (1) CN106559985A (zh)
AU (2) AU2015276237B2 (zh)
CA (1) CA2952103A1 (zh)
ES (5) ES2831865T3 (zh)
HK (3) HK1256730A1 (zh)
IL (1) IL249540B (zh)
NL (1) NL2013007B1 (zh)
PL (5) PL3154569T3 (zh)
PT (5) PT3154569T (zh)
RU (1) RU2704444C2 (zh)
SG (2) SG11201610488QA (zh)
WO (1) WO2015193326A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
CN107340225B (zh) * 2017-07-13 2019-07-05 徐州医科大学 一种基于流式细胞术检测血小板受体GPIba胞外段酶切的方法
US11999797B2 (en) 2018-02-06 2024-06-04 Ablynx N.V. Methods of treating initial episode of TTP with immunoglobulin single variable domains
KR20240058167A (ko) 2021-09-17 2024-05-03 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Sars-cov-2 중화 항체 동정을 위한 합성 인간화 라마 나노바디 라이브러리 및 이의 용도
WO2023108095A1 (en) * 2021-12-10 2023-06-15 Emory University Polypeptides that bind to von willebrand factor (vwf) al domain or an autoinhibitory module, variants, and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1157119A1 (en) 1999-02-05 2001-11-28 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1527346B1 (en) 2002-08-07 2011-06-08 Ablynx N.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
CA2512545C (en) 2003-01-10 2015-06-30 Karen Silence Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
CA2535550A1 (en) 2003-08-12 2005-03-03 William M. Yarbrough Treatment for acne vulgaris and method of use
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
SI1836500T1 (sl) 2005-01-14 2010-11-30 Ablynx Nv Postopki in testi za razlikovanje med različnimioblikami bolezni in motenj ki so označene s trombocitopenijo in ali s spontano interakcijo med von Willebrandovim faktorjem vWF in krvnimi ploščicami
EP2007814A2 (en) * 2005-05-20 2008-12-31 Ablynx N.V. Single domain vhh antibodies against von willebrand factor
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US20110118185A9 (en) 2007-02-21 2011-05-19 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
NZ581097A (en) 2007-05-24 2012-03-30 Ablynx Nv Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2009115614A2 (en) 2008-03-21 2009-09-24 Ablynx Nv Von willebrand factor specific binders and methods of use therefor
EP2362767B1 (en) 2008-10-29 2017-12-06 Ablynx N.V. Formulations of single domain antigen binding molecules
MX2011004558A (es) 2008-10-29 2011-06-01 Wyeth Llc Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
US20120321640A1 (en) 2009-12-01 2012-12-20 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
SG10201505624VA (en) * 2010-11-05 2015-09-29 Novartis Ag Methods of treating rheumatoid arthritis using il-17 antagonists
EP2717905B1 (en) 2011-06-10 2018-05-23 Baxalta GmbH Treatment of coagulation disease by administration of recombinant vwf
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.

Also Published As

Publication number Publication date
PL3335723T3 (pl) 2022-07-18
KR20220053040A (ko) 2022-04-28
EP3335724B1 (en) 2022-06-22
RU2704444C2 (ru) 2019-10-28
JP7105260B2 (ja) 2022-07-22
US20180155442A1 (en) 2018-06-07
EP3154569A1 (en) 2017-04-19
CN106559985A (zh) 2017-04-05
EP3332800B1 (en) 2020-08-26
ES2843642T3 (es) 2021-07-19
ES2881331T3 (es) 2021-11-29
EP3335723A1 (en) 2018-06-20
ES2831865T3 (es) 2021-06-09
RU2017100077A (ru) 2018-07-12
AU2021202747A1 (en) 2021-05-27
JP2022160431A (ja) 2022-10-19
US20180155441A1 (en) 2018-06-07
EP4059513A1 (en) 2022-09-21
ES2915473T3 (es) 2022-06-22
PT3366305T (pt) 2020-12-21
SG11201610488QA (en) 2017-01-27
RU2017100077A3 (zh) 2018-12-25
PT3332800T (pt) 2020-11-19
EP3366305B1 (en) 2020-11-18
US20180155443A1 (en) 2018-06-07
RU2019131713A (ru) 2019-11-11
EP3335724A1 (en) 2018-06-20
PT3335723T (pt) 2022-05-20
IL249540B (en) 2021-09-30
PL3366305T3 (pl) 2021-06-14
AU2015276237A1 (en) 2017-01-19
KR102403388B1 (ko) 2022-06-03
PL3154569T3 (pl) 2021-11-02
NL2013007B1 (en) 2016-07-05
PL3332800T3 (pl) 2021-04-19
AU2015276237B2 (en) 2021-02-25
ES2924199T3 (es) 2022-10-05
KR102568585B1 (ko) 2023-08-18
AU2021202747B2 (en) 2024-02-15
JP6688746B2 (ja) 2020-04-28
PL3335724T3 (pl) 2022-09-19
US10858445B2 (en) 2020-12-08
IL249540A0 (en) 2017-02-28
WO2015193326A1 (en) 2015-12-23
KR20170015513A (ko) 2017-02-08
US20180155440A1 (en) 2018-06-07
JP2017519762A (ja) 2017-07-20
EP3366305A1 (en) 2018-08-29
JP2020097600A (ja) 2020-06-25
EP3154569B1 (en) 2021-04-21
PT3154569T (pt) 2021-06-22
US10919980B2 (en) 2021-02-16
PT3335724T (pt) 2022-08-02
EP3335723B1 (en) 2022-03-30
US20170210822A1 (en) 2017-07-27
HK1256730A1 (zh) 2019-10-04
HK1256731A1 (zh) 2019-10-04
SG10201811109PA (en) 2019-01-30
EP3332800A1 (en) 2018-06-13
CA2952103A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
HK1258058A1 (zh) 抗tigit抗體和使用方法
HK1252697A1 (zh) 抗cd33抗體及其使用方法
HK1252858A1 (zh) 抗cll-1抗體和使用方法
HK1252675A1 (zh) 抗cd33抗體及其使用方法
IL247898A0 (en) Anti-ox40 antibodies and methods of use
HK1258508A1 (zh) 用免疫球蛋白單可變結構域治療ttp的方法及其用途
HK1258850A1 (zh) 抗tpbg抗體及使用方法
IL265568A (en) Methods for treating TIM-3 elevation